This longitudinal study looked at the tolerability as well as the effects of dalfampridine on walking and community participation. Dalfampridine is a potassium channel blocker that enhances conduction in demyelinated nerves and has been shown to improve walking speed in people with MS.
A total of 39 people with both RRMS and progressive MS were prescribed dalfampridine extended release (ER) and 62% (24) of these continued on the treatment over one year. The subjects completed the Timed 25-Foot Walk (T25FW), Multiple Sclerosis Walking Scale-12 (MSWS-12), Two-Minute Walk (2MTW), and Community Integration Questionnaire (CIQ) at baseline and follow-up clinic visits over the following year. Initial results demonstrated a significant improvement in all parameters from baseline, while at one year both walking endurance measured using the 2MWT and MSWS-12 were still significantly improved.
Authors: Cameron MH, Overs S
Source: Mult Scler. 2013 Oct 7. [Epub ahead of print]
Read the abstract